These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 4154848)

  • 1. Beta-adrenoceptor studies. III. On the beta-adrenoceptors in rat adipose tissue.
    Harms HH; Zaagsma J; Van der Wal B
    Eur J Pharmacol; 1974 Jan; 25(1):87-91. PubMed ID: 4154848
    [No Abstract]   [Full Text] [Related]  

  • 2. Nitrilophenoxypropanolamines: influence of ring substitution on beta-receptor blockade.
    Mylecharane EJ; Raper C
    Eur J Pharmacol; 1974 Nov; 29(1):93-101. PubMed ID: 4154862
    [No Abstract]   [Full Text] [Related]  

  • 3. Some adrenergic beta-blocking agents affecting lipolysis in human adipose tissue in vitro.
    Wenkeová J; Kuhn E; Wenke M
    Eur J Pharmacol; 1976 May; 37(1):91-5. PubMed ID: 6293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the adrenoceptors in coronary arteries of pigs.
    Bayer BL; Mentz P; Förster W
    Eur J Pharmacol; 1974 Nov; 29(1):58-65. PubMed ID: 4435045
    [No Abstract]   [Full Text] [Related]  

  • 5. The beta-blocking potency and cardioselectivity of tolamolol and its isomers in rodents.
    Adam KR; Baird JR; Burges RA; Linnell J
    Eur J Pharmacol; 1974 Feb; 25(2):170-5. PubMed ID: 4154851
    [No Abstract]   [Full Text] [Related]  

  • 6. Lipid solubility of vasodilatory vanilloid-type beta-blockers on the functional and binding activities of beta-adrenoceptor subtypes.
    Wu BN; Shen KP; Lin RJ; Huang YC; Chiang LC; Lo YC; Lin CY; Chen IJ
    Gen Pharmacol; 2000 May; 34(5):321-8. PubMed ID: 11368887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiospecificity of -receptor blockade. A comparison of the relative potencies on cardiac and peripheral vascular -adrenoceptors of propranolol, of practolol and its ortho-substituted isomer, and of oxprenolol and its para-substituted isomer.
    Williams EM; Bagwell EE; Singh BN
    Cardiovasc Res; 1973 Mar; 7(2):226-40. PubMed ID: 4144352
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential inhibition of lipolysis in human adipose tissue by adrenergic beta receptor blocking drugs.
    Frisk-Holmberg M; Ostman J
    J Pharmacol Exp Ther; 1977 Mar; 200(3):598-605. PubMed ID: 15099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of beta-adrenergic blocking activities of propranolol, isopropylmethoxamine, sotalol, practolol, alprenolol, pindolol, oxprenolol and D-32 in the atria and trachea of the guinea-pig.
    Horii D; Kawada T; Takeda K; Imai S
    Arzneimittelforschung; 1974 Sep; 24(9):1275-7. PubMed ID: 4154764
    [No Abstract]   [Full Text] [Related]  

  • 11. Selectivity of beta-adrenergic compounds. III - Classification of beta-receptors.
    Grana E; Lucchelli A; Zonta F
    Farmaco Sci; 1974 Oct; 29(10):786-92. PubMed ID: 4154868
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of relative inotropic and chronotropic effects of propranolol, practolol, and sotalol.
    Goldstein RE; Hall CA; Epstein SE
    Chest; 1973 Nov; 64(5):619-27. PubMed ID: 4147980
    [No Abstract]   [Full Text] [Related]  

  • 13. Changes in beta-adrenoceptor-blocking activity produced by chemical modifications in the practolol molecule.
    Weinstock M; Schechter Y; Erez M; Shtacher G
    Eur J Pharmacol; 1974 May; 26(2):191-7. PubMed ID: 4152806
    [No Abstract]   [Full Text] [Related]  

  • 14. Evidence for the participation of beta1-adrenoceptors in isoprenaline-induced renin release from rat kidny slices in vitro.
    Desaulles E; Miesch F; Schwartz J
    Br J Pharmacol; 1978 Jul; 63(3):421-5. PubMed ID: 27279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of salbutamol and butoxamine on the human fat cell adenylate cyclase.
    Kather H; Simon B
    Horm Metab Res; 1980 Dec; 12(12):695-7. PubMed ID: 6259042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isoprenaline antagonism of cardioselective beta-adrenergic receptor blocking agents on human and rat adipocytes.
    Harms HH; Van der Meer J
    Br J Clin Pharmacol; 1975 Aug; 2(4):311-5. PubMed ID: 9950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative relationship between beta-adrenergic receptor number and physiologic responses as studied with a long-lasting beta-adrenergic antagonist.
    Terasaki WL; Linden J; Brooker G
    Proc Natl Acad Sci U S A; 1979 Dec; 76(12):6401-5. PubMed ID: 42915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the B-adrenergic action of oxyfedrine.
    Sakai K; Shiraki Y; Hashimoto K
    Eur J Pharmacol; 1973 Jan; 21(1):81-8. PubMed ID: 4145385
    [No Abstract]   [Full Text] [Related]  

  • 19. Beta-adrenoceptors in the human dorsal hand vein, and the effects of propranolol and practolol on venous sensitivity to noradrenaline.
    White CB; Udwadia BP
    Br J Clin Pharmacol; 1975 Apr; 2(2):99-105. PubMed ID: 186090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capsinolol: the first beta-adrenoceptor blocker with an associated calcitonin gene-related peptide releasing activity in the heart.
    Chen IJ; Yeh JL; Lo YC; Sheu SH; Lin YT
    Br J Pharmacol; 1996 Sep; 119(1):7-14. PubMed ID: 8872350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.